Ten-Year Tally: LLY Hands Back $47 Bil to Shareholders
In the last decade, Eli Lilly (LLY) has returned $47 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let’s look at some numbers and compare how this payout power stacks up against the market’s biggest capital-return machines.
As it turns out, LLY has returned the 59th highest amount to shareholders in history.
| LLY | S&P Median | |
|---|---|---|
| Dividends | $29 Bil | $4.5 Bil |
| Share Repurchase | $18 Bil | $5.5 Bil |
| Total Returned | $47 Bil | $9.1 Bil |
| Total Returned as % of Current Market Cap | 7.3% | 25.9% |
Why should you care? Because dividends and share repurchases represent direct, tangible returns of capital to shareholders. They also signal management’s confidence in the company’s financial health and ability to generate sustainable cash flows. And there are more companies like that. Here is a list of the top 10 companies ranked by total capital returned to shareholders via dividends and stock repurchases.
Top 10 Companies By Total Shareholder Return
- How To Earn 8.2% Yield While Waiting to Buy WYNN 30% Cheaper
- What Could Light a Fire Under Costco Wholesale Stock
- The Hidden Dangers Facing Amazon.com Stock
- Cash Rich, Low Price – Ardent Health Stock to Break Out?
- Momentum Meets Value: Centrus Energy Stock Could Be A Good Buy
- High Margins, 34% Discount: Buy Visa Stock Now
| Total Money Returned | As % Of Current Market Cap | via Dividends | via Share Repurchases | |
|---|---|---|---|---|
| AAPL | $847 Bil | 23.7% | $141 Bil | $706 Bil |
| MSFT | $364 Bil | 9.9% | $165 Bil | $199 Bil |
| GOOGL | $343 Bil | 12.1% | $12 Bil | $331 Bil |
| XOM | $212 Bil | 44.8% | $145 Bil | $67 Bil |
| WFC | $208 Bil | 81.5% | $59 Bil | $150 Bil |
| META | $178 Bil | 9.4% | $7.7 Bil | $171 Bil |
| JPM | $174 Bil | 21.2% | $0.0 | $174 Bil |
| ORCL | $163 Bil | 24.9% | $34 Bil | $129 Bil |
| JNJ | $157 Bil | 36.5% | $104 Bil | $52 Bil |
| CVX | $153 Bil | 57.8% | $97 Bil | $55 Bil |
For full ranking, visit Buybacks & Dividends Ranking
What do you notice here? The total capital returned to shareholders as a % of the current market cap appears inversely proportional to growth prospects for reinvestments. Companies like META and MSFT are growing much faster, in a more predictable way, compared to the others, but they have returned a much lower fraction of their market cap to shareholders.
That’s the flip side to high capital returns. Sure, they are attractive, but you have to ask yourself the question: Am I sacrificing growth and sound fundamentals? With that in mind, let’s look at some numbers for LLY. (see Buy or Sell LLY Stock for more details)
LLY Fundamentals
- Revenue Growth: 36.8% LTM and 23.4% last 3-year average.
- Cash Generation: Nearly -0.09% free cash flow margin and 43.0% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for LLY was 1.5%.
- Valuation: LLY trades at a P/E multiple of 48.0
- Opportunity vs S&P: Compared to S&P, you get higher valuation, higher revenue growth, and better operating margins
| LLY | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 48.0 | 24.1 |
|
|
||
| LTM* Revenue Growth | 36.8% | 5.1% |
| 3Y Average Annual Revenue Growth | 23.4% | 5.3% |
| Min Annual Revenue Growth Last 3Y | 1.5% | -0.1% |
|
|
||
| LTM* Operating Margin | 43.0% | 18.7% |
| 3Y Average Operating Margin | 35.6% | 17.9% |
| LTM* Free Cash Flow Margin | -0.1% | 13.4% |
*LTM: Last Twelve Months
That’s a good overview, but evaluating a stock from an investment perspective involves much more. That is exactly what Trefis High Quality Portfolio does. It is designed to reduce stock-specific risk while giving upside exposure.
LLY Historical Risk
That said, Lilly isn’t immune to big drops. It fell 51% during the Global Financial Crisis and 43% in the Dot-Com bubble. Even in more recent turbulence, like the 2018 correction, inflation shock, and Covid pandemic, it still saw declines between 18% and 22%. So, despite strong fundamentals, this stock can take a noticeable hit when markets turn sour.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.